Graf Acquisition
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch GFOR and buy or sell other stocks, ETFs, and their options commission-free!About GFOR
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression.
CEOPaul Y. Song, MD, PhD
CEOPaul Y. Song, MD, PhD
Employees26
Employees26
HeadquartersSanta Ana, California
HeadquartersSanta Ana, California
Founded
Founded
Employees26
Employees26
GFOR Key Statistics
Market cap2.21M
Market cap2.21M
Price-Earnings ratio-0.04
Price-Earnings ratio-0.04
Dividend yield—
Dividend yield—
Average volume8.37K
Average volume8.37K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.91
52 Week high$0.91
52 Week low$0.0002
52 Week low$0.0002
Stock Snapshot
With a market cap of 2.21M, Graf Acquisition(GFOR) trades at $0.05. The stock has a price-to-earnings ratio of -0.04.
On 2025-12-30, Graf Acquisition(GFOR) stock opened at —, reached a high of —, and a low of —.
The Graf Acquisition(GFOR)'s current trading volume is 0, compared to an average daily volume of 8.37K.
During the past year, Graf Acquisition(GFOR) stock moved between $0.00 at its lowest and $0.91 at its peak.
During the past year, Graf Acquisition(GFOR) stock moved between $0.00 at its lowest and $0.91 at its peak.
People also own
Based on the portfolios of people who own GFOR. This list is generated using Robinhood data, and it’s not a recommendation.